# An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

> **NCT00191646** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 919 (actual)

## Conditions studied

- Genital Neoplasms, Female
- Fallopian Tube Neoplasms
- Ovarian Neoplasms
- Pelvic Neoplasms
- Peritoneal Neoplasms

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00191646
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 919 (ACTUAL)
- **Last updated:** 2011-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191646, "An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00191646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*